April 2026 Research Update

This month added a clearer reminder that stiff person syndrome can appear as part of broader autoimmune conditions defined by specific antibodies, and that the details of the antibody pattern may matter for what else is going on in the body. In a small group of people with anti-amphiphysin antibodies, symptoms were not limited to stiffness and spasms, and one person had lung cancer. The report also described that having more than one nervous system antibody at the same time might signal higher tumor risk, although this was based on very limited numbers. [1]

In the four reported anti-amphiphysin-positive cases, the neurologic problems varied and included stiff person syndrome in one person and spinal cord involvement (myelitis or lower spinal nerve involvement) in others. Some people had anti-amphiphysin antibodies alone, while others had additional antibodies (AQP4-IgG or NMDAR-IgG). The authors described that some patients can stabilize or improve when immunotherapy is combined with cancer treatment, but the report does not provide enough detail to know how often this happens or for whom. [1]

For patients, this mainly adds context about why antibody testing can be part of understanding an SPS diagnosis and why some SPS-like presentations prompt attention to possible cancer links, especially in anti-amphiphysin-associated illness. The evidence here comes from only four patients plus a literature review, so it cannot tell an individual person what will happen. What it does help clarify is that SPS is not a single uniform condition, and the antibody subtype can be tied to different symptom patterns and, sometimes, to a tumor being present. [1]

One report this month highlighted that symptoms in stiff person syndrome can sometimes worsen after a new medication is started, and that the change can be dramatic enough to include new eye movement problems. In a single patient, symptoms worsened after tandospirone was started, and the level of GAD antibodies rose at the same time. After treatment with rituximab and intravenous immunoglobulin (IVIG), her symptoms improved. [2]

Because this was a single-person report, it cannot show that tandospirone will trigger worsening in other people with SPS, or that the same treatment approach will work for everyone. It does, however, give a concrete example of how changes in symptoms and immune markers can move together in an individual case, and how immunotherapy was used when the condition escalated. It also expands the range of symptoms described in SPS by including ophthalmoplegia (trouble moving the eyes), which may be confusing if it appears unexpectedly. [2]

For patients and caregivers, this is mainly an early signal rather than a general rule. It suggests that, in rare situations, a new medication could coincide with a flare of SPS symptoms and even new neurologic symptoms, but it does not prove cause and effect. The most practical value is added awareness that sudden changes after starting a new drug have been reported in at least one person, and that immune-based treatments were part of the recovery in that case. [2]

Lab research this month made it clearer that glycine receptor antibodies in SPS do not all latch onto the same single spot, which may help explain why patients can differ. Researchers mapped several binding areas on glycine receptors and found that some people had antibodies that could be blocked by a specific small protein piece, while others had antibodies that were only partly blocked. This pattern supports the idea that many patients have a mixture of antibody types targeting more than one region. [3]

In these experiments, engineered receptor fragments and overlapping peptides were used to see whether patient antibodies could be neutralized (blocked) in a cell-based test. One patient serum could be fully neutralized by a particular peptide sequence, but other sera still showed antibody activity even when binding was reduced. This suggests that a single "decoy" peptide may not be enough for every patient, at least with the antibody mixtures tested here. [3]

For patients, this does not change day-to-day care right now because it is laboratory research, not a treatment study. What it adds is a clearer explanation for why "having glycine receptor antibodies" may not mean the same thing for every person: different people can have antibodies that recognize different parts of the receptor. If future therapies are designed to block or remove these antibodies more precisely, this kind of mapping could matter later, but it is not yet ready for clinical decision-making. [3]